Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer
Abstract In the field of oncology research, a deeper understanding of tumor biology has shed light on the role of environmental conditions surrounding cancer cells. In this regard, targeting the tumor microenvironment has recently emerged as a new way to access this disease. In this work, a novel ex...
Guardado en:
Autores principales: | Alessandro De Vita, Chiara Liverani, Roberto Molinaro, Jonathan O. Martinez, Kelly A. Hartman, Chiara Spadazzi, Giacomo Miserocchi, Francesca Taraballi, Michael Evangelopoulos, Federica Pieri, Alberto Bongiovanni, Laura Mercatali, Ennio Tasciotti, Toni Ibrahim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f3592b74807643ad8fc46e879476242d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
por: Ozge Saatci, et al.
Publicado: (2020) -
An in situ activity assay for lysyl oxidases
por: Huilei Wang, et al.
Publicado: (2021) -
Author Correction: An in situ activity assay for lysyl oxidases
por: Huilei Wang, et al.
Publicado: (2021) -
Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas
por: Alessandro De Vita, et al.
Publicado: (2021) -
Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse
por: Long T. Nguyen, et al.
Publicado: (2021)